# US 2025/0164463 A1 · Screening method and therapeutic agent for mental disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164463 A1
- Document ID: US20250164463A1
- Status: Published application
- Kind: A1
- Application number: 18/838,384
- Filed: 2022-11-30
- Published: 2025-05-22
- Earliest claimed: 2022-02-14
- Assignees: Fujita Health University
- Applicants: Fujita Health University
- Inventors: Kazuo KUNISAWA; Akihiro MOURI; Toshitaka NABESHIMA
- Web page: https://patentgrep.com/patent/US20250164463A1

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- G01N 33/5058: {Neurological cells}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- G01N 33/5088: {of vertebrates}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a novel therapeutic agent for a mental disorder and a screening method for a therapeutic agent for a mental disorder. The therapeutic agent for a mental disorder includes clemastine or a pharmacologically acceptable salt thereof as an active ingredient. According to the therapeutic agent of the present invention, myelin sheath abnormality and brain dysfunction due to a mental disorder can be mitigated. Further, through use of the screening method of the present invention, a therapeutic agent for a mental disorder can be screened for.

## Claims

### Claim 1

A therapeutic agent for a mental disorder in a subject, comprising clemastine or a pharmacologically acceptable salt thereof as an active ingredient.

### Claim 2 (depends on 1)

The therapeutic agent according to claim 1, wherein the mental disorder is an alcohol use disorder.

### Claim 3 (depends on 2)

The therapeutic agent according to claim 2, wherein the alcohol use disorder is alcoholic brain dysfunction.

### Claim 4

A screening method for a therapeutic agent for a mental disorder in a subject, comprising screening for an oligodendrocyte differentiation enhancing substance.

### Claim 5 (depends on 4)

The screening method for a therapeutic agent for a mental disorder according to claim 4, comprising a step of measuring an amount of expression of an oligodendrocyte marker.

### Claim 6 (depends on 4)

The screening method according to claim 4, wherein the mental disorder is an alcohol use disorder.

### Claim 7 (depends on 6)

The screening method according to claim 6, wherein the alcohol use disorder is alcoholic brain dysfunction.

### Claim 8 (depends on 4)

The screening method according to claim 4, further comprising a step of collecting a test sample from a subject, to which a candidate substance has been administered, or a step of incubating oligodendrocytes with a candidate substance added thereto.

### Claim 9 (depends on 4)

The screening method according to claim 4, comprising at least the following steps (1) to (3):
(1) collecting a test sample from a subject to which a candidate substance has been administered;
(2) measuring, in the test sample, an expression amount of each of one or a plurality of kinds of oligodendrocyte markers selected from MAG, CNPase, CC1, Olig2, MBP, PDGFRα, and NG2; and
(3) selecting the candidate substance as the oligodendrocyte differentiation enhancing substance when the expression amount of each of the one or the plurality of oligodendrocyte markers is enhanced in the subject with the candidate substance administered thereto as compared to a subject without the candidate substance.

### Claim 10

A method of examining prognosis of a mental disorder in a subject, comprising measuring, in a test sample collected from a human subject, one or a plurality of kinds of molecules selected from oligodendrocyte markers, oligodendrocyte differentiation modulators, oligodendrocyte differentiation regulators, and oligodendrocyte-derived products.

### Claim 11 (depends on 1)

The therapeutic agent according to claim 1, wherein the mental disorder is schizophrenia.

### Claim 12 (depends on 2)

The therapeutic agent according to claim 2, wherein the alcohol use disorder is myelin sheath abnormality.

### Claim 13 (depends on 4)

The screening method according to claim 4, wherein the mental disorder is schizophrenia.

### Claim 14 (depends on 6)

The screening method according to claim 6, wherein the alcohol use disorder is myelin sheath abnormality.

### Claim 15 (depends on 10)

The method of examining prognosis of a mental disorder in a subject according to claim 10, wherein the mental disorder is an alcohol use disorder.

### Claim 16 (depends on 15)

The method of examining prognosis of a mental disorder in a subject according to claim 15, wherein the alcohol use disorder is alcoholic brain dysfunction.

### Claim 17 (depends on 15)

The method of examining prognosis of a mental disorder in a subject according to claim 15, wherein the alcohol use disorder is myelin sheath abnormality.

### Claim 18

A method of treating a mental disorder in a subject, comprising administering an effective amount of clemastine or a pharmacologically acceptable salt thereof to a person in need thereof.

### Claim 19 (depends on 18)

The treatment method according to claim 18, wherein the mental disorder is an alcohol use disorder and/or schizophrenia.

### Claim 20 (depends on 19)

The treatment method according to claim 19, wherein the alcohol use disorder is an alcoholic brain dysfunction and/or myelin sheath abnormality.
